By Josh White
Date: Thursday 09 May 2024
(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.
The London-listed firm said Gaucher disease, a genetic disorder stemming from GCase enzyme deficiency,...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news